Inmed Pharmaceuticals INC

InMed Pharmaceuticals and Mentari Therapeutics announced an amendment to their merger agreement, increasing the pre-closing private placement financing to $200 million.

InMed Pharmaceuticals and Mentari Therapeutics have amended their merger agreement, clarifying transaction sequencing, pre-closing financing impacts, and tax treatment, while also filing a Form S-4 registration statement.

InMed Pharmaceuticals Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a matter previously flagged in March 2026.

InMed Pharmaceuticals Inc. announced a definitive merger agreement with Mentari Therapeutics, Inc., a biotechnology company focused on migraine prevention therapies, aiming to advance Mentari's pipeline with a concurrent $290 million private placement.

InMed Pharmaceuticals Inc. has amended preferred investment options with Armistice Capital Master Fund Ltd., reducing the exercise price from $16.60 to $0.80 per share.

InMed Pharmaceuticals has reduced the exercise price of existing preferred investment options to $0.80 per share for Sabby and H.C. Wainwright affiliates.

InMed Pharmaceuticals reports Q3 2026 financial results, highlighting the wind-down of its BayMedica commercial segment and a focus on its pharmaceutical pipeline.

InMed Pharmaceuticals reported a reduced net loss and increased cash, but faces significant uncertainty from new U.S. legislation impacting its BayMedica subsidiary and ongoing legal disputes, alongside a stated going concern doubt.

InMed Pharmaceuticals Inc. reported an increased net loss for Q1 2026, alongside a going concern warning and a significant legal dispute impacting its commercial segment.

InMed Pharmaceuticals reports a net loss for Q3 2025 and expresses concerns about its ability to continue as a going concern without additional funding.

InMed Pharmaceuticals announces its financial results for the quarter ended December 31, 2024, and provides updates on its pharmaceutical development programs and commercial operations.

InMed Pharmaceuticals reported its financial results for the quarter ended September 30, 2024, while also addressing its Nasdaq listing compliance through a reverse stock split.

InMed Pharmaceuticals Inc. filed an amendment to its annual report, providing detailed disclosures on executive compensation, corporate governance, and director independence for the fiscal year ended June 30, 2025.

InMed Pharmaceuticals Inc. reported its fiscal year 2025 results, highlighting progress in its Alzheimer's and dry AMD drug candidates, alongside revenue growth in its BayMedica segment, despite ongoing operating losses and a going concern doubt.

InMed Pharmaceuticals Inc. releases its annual report, highlighting advancements in its drug development programs and providing a financial overview for the fiscal year ended June 30, 2024.

InMed Pharmaceuticals and Mentari Therapeutics announce a merger to advance novel migraine prevention therapies, backed by significant private placement funding.

InMed Pharmaceuticals Inc. and Mentari Therapeutics, Inc. announced an amendment to their merger agreement, increasing Mentari's pre-closing private placement financing to $200 million.

Mentari Therapeutics announces Greg Divis as new CEO, advancing migraine therapies as it merges with InMed Pharmaceuticals.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of InMed Pharmaceuticals Inc. common stock on July 15, 2026.

Vivo Opportunity, LLC and 3 others reported changes in beneficial ownership of InMed Pharmaceuticals Inc. common stock on July 14, 2026.

InMed Pharmaceuticals and Mentari Therapeutics have amended their merger agreement, clarifying transaction sequencing, pre-closing financing impacts, and tax treatment, while also filing a Form S-4 registration statement.

InMed Pharmaceuticals Inc. announces its 2025 Annual General and Special Meeting to be held virtually on December 17, 2025, seeking shareholder approval for director elections, auditor appointment, and a significant share issuance under a standby equity purchase agreement.

InMed Pharmaceuticals Inc. announces its Annual General and Special Meeting on December 17, 2025, seeking shareholder approval for director elections, auditor reappointment, and a potential equity issuance of 20% or more of common shares.

InMed Pharmaceuticals Inc. is reminding shareholders to vote on a proposal to approve the potential issuance of 20% or more of its common shares under a Standby Equity Purchase Agreement (SEPA) to secure future funding.

InMed Pharmaceuticals is seeking shareholder approval to potentially issue 20% or more of its common shares under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (Yorkville), as required by Nasdaq Listing Rules.

InMed Pharmaceuticals will hold its annual general meeting virtually on December 18, 2024, to discuss financial statements, elect directors, and appoint auditors.

InMed Pharmaceuticals will hold its 2024 Annual General Meeting virtually on December 18, 2024, and is using notice-and-access rules for delivering meeting materials to shareholders.

InMed Pharmaceuticals Inc. filed an S-1/A registration statement for the resale of common shares by a selling shareholder, while detailing its drug development pipeline, financial results, and ongoing capital needs.

InMed Pharmaceuticals Inc. has filed an S-1 registration statement to allow a selling shareholder to resell up to 3,904,726 common shares, stemming from a recent private placement that provided the company with potential proceeds of approximately $4.76 million from warrant and option exercises, while the company continues to face significant operating losses and a substantial accumulated deficit.

InMed Pharmaceuticals has filed a pre-effective amendment to its S-1 registration statement, primarily to include updated legal opinions and consents related to a potential offering of common shares.

InMed Pharmaceuticals has filed a registration statement for the potential resale of up to 3 million common shares by a selling shareholder, following a Standby Equity Purchase Agreement.

Vivo Opportunity Fund Holdings and affiliates have disclosed a 21.7% beneficial ownership stake in InMed Pharmaceuticals following a merger announcement.

ADAR1 Capital Management and Daniel Schneeberger have reported a 24.1% beneficial ownership stake in InMed Pharmaceuticals, Inc.

Squadron Master Fund LP, along with its affiliates, has disclosed beneficial ownership of 325,000 shares, representing 9.8% of InMed Pharmaceuticals Inc.'s common stock.

Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have disclosed a 9.9% beneficial ownership stake in InMed Pharmaceuticals Inc.

AdvisorShares Trust has filed an amended Schedule 13G, disclosing that it no longer holds any beneficial ownership in InMed Pharmaceuticals Inc.

Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly reported a passive beneficial ownership of 4.9% in InMed Pharmaceuticals Inc.'s common stock as of December 31, 2024.